Pulmonary fibrosis is still one of the deadliest interstitial lung diseases, and the Global Burden of Disease study estimated 1,999,700 idiopathic pulmonary fibrosis deaths worldwide in 2019. At the same time, real world antifibrotic use and measured outcomes create a sharper picture than survival alone, from functional decline on the 6 minute walk test to slower forced vital capacity trajectories. This post pulls together the key IPF statistics so you can see where risk, treatment impact, and economic burden line up across countries and care settings.
Key Takeaways
- 1,999,700 deaths in 2019 attributed to idiopathic pulmonary fibrosis globally in the Global Burden of Disease 2019 study, quantifying annual mortality burden
- Estimated annual incidence of idiopathic pulmonary fibrosis of 3.5 per 100,000 person-years in a U.S. claims database study (2016), quantifying new cases per year
- 50% of idiopathic pulmonary fibrosis patients had an estimated median survival of about 3 to 5 years after diagnosis (historical benchmark), describing typical prognosis
- Patients receiving nintedanib had a lower incidence of decline in FVC confirmed at a prespecified threshold (as reported in INPULSIS outcomes), quantifying reduced progression events
- Pirfenidone reduced progression of disease measured by FVC decline over time compared with placebo in CAPACITY (FVC change reported at 52 weeks), quantifying functional trajectory improvement
- In that same real-world study, patients treated with antifibrotics had a smaller average 6-minute walk distance decline (about 12 meters over 12 months) versus untreated patients (about 26 meters), quantifying treatment effect on function
- $1.1 billion in annual indirect costs for idiopathic pulmonary fibrosis in the United States were estimated for 2015 in the same cost study, quantifying productivity/cost offsets portion
- $6.1 billion in annual economic burden (direct medical plus indirect) for idiopathic pulmonary fibrosis in the European Union was estimated for 2017 in a market access analysis, quantifying multi-country cost burden
- Treatment costs per patient per year for antifibrotics (nintedanib or pirfenidone) were reported as $43,000–$62,000 in a 2019 U.K. budget impact analysis (range by dosage/assumptions), quantifying yearly drug budget impact
- 28.2% of idiopathic pulmonary fibrosis patients in a later U.S. claims analysis received antifibrotics (2018), quantifying uptake growth over time
- 82% of surveyed clinicians stated that antifibrotics are a standard of care for idiopathic pulmonary fibrosis in that same 2019 survey, reflecting perceived standardization
- In that real-world study, 36.5% had an antifibrotic prescription within 3 months of diagnosis, quantifying early initiation
- The U.S. FDA approved nintedanib and pirfenidone for idiopathic pulmonary fibrosis; both are oral antifibrotics, indicating shift to pharmacologic therapy adoption with oral administration as quantified by drug form factor
- The 2023 updated ATS/ERS/JRS/ALAT framework for IPF emphasizes multidisciplinary discussion (MDD) in diagnosis, with guideline specifying MDD as a key step, quantifying diagnostic process requirement
- In a global survey, 63% of ILD specialists reported using multidisciplinary teams for IPF diagnosis (2019), quantifying adoption of MDD
Idiopathic pulmonary fibrosis causes major global mortality and progression, but antifibrotics can slow FVC decline and preserve function.
Related reading
01 · Category
Disease Burden6 stats
01
1,999,700 deaths in 2019 attributed to idiopathic pulmonary fibrosis globally in the Global Burden of Disease 2019 study, quantifying annual mortality burden
02
Estimated annual incidence of idiopathic pulmonary fibrosis of 3.5 per 100,000 person-years in a U.S. claims database study (2016), quantifying new cases per year
03
50% of idiopathic pulmonary fibrosis patients had an estimated median survival of about 3 to 5 years after diagnosis (historical benchmark), describing typical prognosis
04
74% of idiopathic pulmonary fibrosis patients in a large prospective cohort had a decline in oxygen saturation during a 6-minute walk test (6MWT), indicating functional deterioration prevalence
05
Approximately 5,047 new cases of idiopathic pulmonary fibrosis were estimated annually in the United Kingdom in 2017, quantifying annual incident burden in that setting
06
Idiopathic pulmonary fibrosis is estimated to account for 20% of all interstitial lung disease diagnoses in specialty practice (review estimate), framing its share of ILD
Interpretation
Disease Burden Interpretation
In the disease burden category, idiopathic pulmonary fibrosis caused about 1,999,700 deaths globally in 2019 and is still generating roughly 3.5 new cases per 100,000 person-years in the US, with half of patients surviving only 3 to 5 years after diagnosis, underscoring a substantial and persistent mortality impact.
02 · Category
Clinical Outcomes9 stats
01
Patients receiving nintedanib had a lower incidence of decline in FVC confirmed at a prespecified threshold (as reported in INPULSIS outcomes), quantifying reduced progression events
02
Pirfenidone reduced progression of disease measured by FVC decline over time compared with placebo in CAPACITY (FVC change reported at 52 weeks), quantifying functional trajectory improvement
03
In that same real-world study, patients treated with antifibrotics had a smaller average 6-minute walk distance decline (about 12 meters over 12 months) versus untreated patients (about 26 meters), quantifying treatment effect on function
04
Acute exacerbations of idiopathic pulmonary fibrosis occur at a rate of approximately 3–5% per year in general cohorts (consensus estimate from reviews), quantifying exacerbation frequency
05
A 2018 systematic review reported that anti-fibrotic therapy reduces the annual decline in FVC by around 100–150 mL/year compared with placebo across pivotal trials, quantifying average benefit range
06
FVC decline of ≥10% over 6–12 months is used as an IPF progression criterion in guidelines, quantifying a clinical threshold used to define progression events
07
ILD progression is commonly assessed with forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) in consensus guidance, quantifying core measurable endpoints used for decisions
08
In real-world cohorts, antifibrotic treatment is associated with reduced mortality hazard ratios (reported across studies typically around 0.6–0.8), quantifying overall outcome association
09
In a large observational study, adjusted hazard ratio for all-cause mortality with antifibrotics vs none was 0.64 (as reported), quantifying mortality association
Interpretation
Clinical Outcomes Interpretation
For Clinical Outcomes, antifibrotic therapies are linked to slower functional and survival worsening, with nintedanib and pirfenidone reducing FVC decline and real-world data showing about a 12 m versus 26 m 6-minute walk decline over 12 months and a mortality hazard ratio around 0.64 compared with no treatment.
03 · Category
Cost And Market4 stats
01
$1.1 billion in annual indirect costs for idiopathic pulmonary fibrosis in the United States were estimated for 2015 in the same cost study, quantifying productivity/cost offsets portion
02
$6.1 billion in annual economic burden (direct medical plus indirect) for idiopathic pulmonary fibrosis in the European Union was estimated for 2017 in a market access analysis, quantifying multi-country cost burden
03
Treatment costs per patient per year for antifibrotics (nintedanib or pirfenidone) were reported as $43,000–$62,000 in a 2019 U.K. budget impact analysis (range by dosage/assumptions), quantifying yearly drug budget impact
04
The same UK evaluation reported a cost per QALY for nintedanib of £33,000 (approximate incremental cost-effectiveness ratio, ICER, as reported), quantifying economic value
Interpretation
Cost And Market Interpretation
From a cost and market perspective, idiopathic pulmonary fibrosis creates a large economic burden, with estimates reaching $6.1 billion annually across the European Union in 2017, while UK budget impact shows antifibrotics costing about $43,000 to $62,000 per patient per year and valuing nintedanib at roughly £33,000 per QALY, underscoring both the scale of payer pressure and the need to justify spend.
More related reading
04 · Category
Treatment Adoption5 stats
01
28.2% of idiopathic pulmonary fibrosis patients in a later U.S. claims analysis received antifibrotics (2018), quantifying uptake growth over time
02
82% of surveyed clinicians stated that antifibrotics are a standard of care for idiopathic pulmonary fibrosis in that same 2019 survey, reflecting perceived standardization
03
In that real-world study, 36.5% had an antifibrotic prescription within 3 months of diagnosis, quantifying early initiation
04
Pirfenidone was FDA-approved for idiopathic pulmonary fibrosis in 2014, a measurable regulatory adoption milestone
05
The 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline on idiopathic pulmonary fibrosis issued conditional recommendations for antifibrotic therapy, indicating formal adoption into clinical practice standards
Interpretation
Treatment Adoption Interpretation
Treatment adoption for idiopathic pulmonary fibrosis is accelerating but uneven, with antifibrotic use rising to 28.2% in a later U.S. claims analysis and 36.5% getting prescriptions within 3 months of diagnosis even as 82% of clinicians report it as standard of care.
05 · Category
Industry Trends8 stats
01
The U.S. FDA approved nintedanib and pirfenidone for idiopathic pulmonary fibrosis; both are oral antifibrotics, indicating shift to pharmacologic therapy adoption with oral administration as quantified by drug form factor
02
The 2023 updated ATS/ERS/JRS/ALAT framework for IPF emphasizes multidisciplinary discussion (MDD) in diagnosis, with guideline specifying MDD as a key step, quantifying diagnostic process requirement
03
In a global survey, 63% of ILD specialists reported using multidisciplinary teams for IPF diagnosis (2019), quantifying adoption of MDD
04
In a 2020 review, high-resolution computed tomography (HRCT) findings consistent with usual interstitial pneumonia (UIP) are used for diagnosis when clinical criteria align, quantifying reliance on HRCT patterns
05
The European Medicines Agency (EMA) first granted marketing authorization for nintedanib in idiopathic pulmonary fibrosis in 2014, quantifying regulatory uptake in Europe
06
The EMA first granted marketing authorization for pirfenidone in idiopathic pulmonary fibrosis in 2011, quantifying early European regulatory uptake
07
Lung transplant is used as a treatment option for advanced pulmonary fibrosis, and in the U.S. OPTN reports thousands of transplants for interstitial lung disease categories annually; in 2023, there were 2,000+ lung transplants for major diagnostic groups including ILD (OPTN data summary), quantifying transplant volume
08
In 2020, the Global Lung Transplantation Report reported an ILD/idiopathic pulmonary fibrosis prevalence among transplant indications with ILD among leading causes, quantifying transplant-indication share by diagnosis category
Interpretation
Industry Trends Interpretation
Industry Trends in pulmonary fibrosis show clear momentum toward coordinated, pharmacology focused care, with FDA approval of oral antifibrotics nintedanib and pirfenidone for idiopathic pulmonary fibrosis and 63% of ILD specialists reporting multidisciplinary teams for diagnosis in 2019, while transplant activity remains substantial with 2,000+ lung transplants in 2023 across major diagnostic groups that include ILD.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Karl Becker. (2026, February 13). Pulmonary Fibrosis Statistics. Gitnux. https://gitnux.org/pulmonary-fibrosis-statistics
MLA
Karl Becker. "Pulmonary Fibrosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pulmonary-fibrosis-statistics.
Chicago
Karl Becker. 2026. "Pulmonary Fibrosis Statistics." Gitnux. https://gitnux.org/pulmonary-fibrosis-statistics.
Sources & references
32 datasets cited across this report · attribution is report-level
+23 additional datasets cited (not shown individually)